Next-Generation Endocrine Therapies for Breast Cancer
Donald P. McDonnell, Suzanne E. Wardell, Ching‐yi Chang, John D. Norris
Abstract
Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. January 29, 2021 ARTICLE CITATION DOI: 10.1200/JCO.20.03565 Journal of Clinical Oncology - published online before print March 11, 2021 PMID: 33705209 Next-Generation Endocrine Therapies for Breast Cancer Donald P. McDonnell , PhD1xDonald P. McDonnellSearch for articles by this author; Suzanne E. Wardell , PhD1xSuzanne E. WardellSearch for articles by this author; Ching-Yi Chang, PhD1xChing-Yi ChangSearch for articles by this author; and John D. Norris, PhD1xJohn D. NorrisSearch for articles by this author Show More 1Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC https://doi.org/10.1200/JCO.20.03565 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologySUPPORTSome of the work described in this manuscript was supported by a DOD Innovator grant, BC170954.AUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: Donald P. McDonnellData analysis and interpretation: Donald P. McDonnellManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTNext-Generation Endocrine Therapies for Breast CancerThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Donald P. McDonnellEmployment: Duke UniversityStock and Other Ownership Interests: Zentalis, G1 Therapeutics, Viba Therapeutics, Rappta Therapeutics, X-RAD TherapeuticsHonoraria: NovartisConsulting or Advisory Role: Zentalis, G1 therapeutics, Bristol-Myers Squibb, Rappta TherapeuticsResearch Funding: Bristol-Myers Squibb, Novartis, ZentalisPatents, Royalties, Other Intellectual Property: Inventor on two patents (assigned to Duke) licensed to Radius Health covering the use of Rad1901 for Breast cancer. I am an inventor on two patents (assigned to Duke) that covers the use of lasofoxifene for ESR1-mutant breast cancers. Licensed to SermonixTravel, Accommodations, Expenses: Bristol-Myers SquibbSuzanne E. WardellConsulting or Advisory Role: ZentalisResearch Funding: Zentalis, Bristol-Myers SquibbPatents, Royalties, Other Intellectual Property: I am listed as an inventor on a patent for the use of RAD1901 in metastatic breast cancerChing-Yi ChangResearch Funding: Novartis Institutes for BioMedical Research, Bristol-Myers SquibbPatents, Royalties, Other Intellectual Property: Sermonix. Patent application for the use of lasofoxifene as treatment for breast cancerJohn D. NorrisConsulting or Advisory Role: G1 Pharmaceuticals, CelgeneResearch Funding: G1 Therapeutics, CelgeneNo other potential conflicts of interest were reported. Companion Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer